Pediatric clinical pharmacology studies in Chagas disease: Focus on Argentina

Pediatric Drugs

Volumn 11, Issue 1, 2009, Pages 33-37

  Garcia Bournissen, Facundo ^a   Altcheh, Jaime ^b   Giglio, Norberto ^b   Mastrantonio, Guido ^c   Omar Della Védova, Carlos ^c   Koren, Gideon ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b HOSPITAL DE NIÑOS RICARDO GUTIÉRREZ   (Argentina)

^c UNIVERSIDAD NACIONAL DE LA PLATA   (Argentina)

Author keywords

Chagas' disease; Children; Pharmacology

Indexed keywords

BENZNIDAZOLE; NIFURTIMOX;

ANOREXIA; ARGENTINA; ARTHRALGIA; CHAGAS DISEASE; CHILD; CHRONIC DISEASE; CLINICAL PHARMACOLOGY; CONFERENCE PAPER; DISEASE COURSE; DRUG EFFICACY; DRUG METABOLISM; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GRANULOCYTOPENIA; HEADACHE; HUMAN; INFANT; MACULOPAPULAR RASH; NAUSEA; PERIPHERAL NEUROPATHY; PRESCHOOL CHILD; PRIORITY JOURNAL; PRURITUS; RASH; SCHOOL CHILD;

ARGENTINA; CHAGAS CARDIOMYOPATHY; CHAGAS DISEASE; CHILD; DRUG ADMINISTRATION SCHEDULE; HUMANS; NIFURTIMOX; NITROIMIDAZOLES; TRYPANOCIDAL AGENTS;

EID: 58149350101     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/0148581-200911010-00012     Document Type: Conference Paper

References (60)

1. Urbina JA, Docampo R. Specific chemotherapy of Chagas disease: controversies and advances. Trends Parasitol 2003; 19 (11): 495-501
2. Schmunis GA. Epidemiology of Chagas disease in non-endemic countries: the role of international migration. Mem Inst Oswaldo Cruz 2007; 102 Suppl. 1: 75-85
3. WHO Expert Committee on the Control of Chagas Disease, World Health Organization. Control of Chagas disease: Second report of the WHO Expert Committee. 905ed. Geneva: World Health Organization, 2002
4. Schmunis GA. Risk of Chagas disease through transfusions in the Americans [in Spanish]. Medicina (B Aires) 1999; 59 Suppl. 2: 125-34
5. Freilij H, Altcheh J. Congenital Chagas' disease: diagnostic and clinical aspects. Clin Infect Dis 1995; 21 (3): 551-5
6. Gurtler RE, Segura EL, Cohen JE. Congenital transmission of Trypanosoma cruzi infection in Argentina. Emerg Infect Dis 2003; 9 (1): 29-32
7. Teixeira AR, Nascimento RJ, Sturm NR. Evolution and pathology in Chagas disease: a review. Mem Inst Oswaldo Cruz 2006; 101 (5): 463-91
8. Berenstein A, Tarlovsky A, Siniawsky S, Delliafonte A, Ibarra S, Callapa J, Moscatelli G, Biancardi M, Folini ME, García M, and Freilij H y Altcheh J. Estudio de prevalencia de enfermedad de Chagas en Centros de Salud de la ciudad de Buenos Aires. 34to Congreso Argentino de Pediatría, ciudad de Córdoba, Argentina. 2006
9. Raether W, Hanel H. Nitroheterocyclic drugs with broad spectrum activity. Parasitol Res 2003; 90 Suppl. 1: S19-39
10. Moreno SN, Docampo R, Mason RP, et al. Different behaviors of benznidazole as free radical generator with mammalian and Trypanosoma cruzi microsomal preparations. Arch Biochem Biophys 1982; 218 (2): 585-91
11. Docampo R. Sensitivity of parasites to free radical damage by antiparasitic drugs. Chem Biol Interact 1990; 73 (1): 1-27
12. Lau AH, Lam NP, Piscitelli SC, et al. Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives. Clin Pharmacokinet 1992; 23 (5): 328-64
13. Raaflaub J, Ziegler WH. Single-dose pharmacokinetics of the trypanosomicide benznidazole in man. Arzneimittelforschung 1979; 29 (10): 1611-4
14. Raaflaub J. Multiple-dose kinetics of the trypanosomicide benznidazole in man. Arzneimittelforschung 1980; 30 (12): 2192-4
15. Richle RW, Raaflaub J. Difference of effective antitrypanosomal dosages of benznidazole in mice and man: chemotherapeutic and pharmacokinetic results. Acta Trop 1980; 37 (3): 257-61
16. Workman P, White RA, Walton MI, et al. Preclinical pharmacokinetics of benznidazole. Br J Cancer 1984; 50 (3): 291-303
17. Lee FY, Workman P. Altered pharmacokinetics in the mechanism of chemosensitization: effects of nitroimidazoles and other chemical modifiers on the pharmacokinetics, antitumour activity and acute toxicity of selected nitrogen mustards. Cancer Chemother Pharmacol 1986; 17 (1): 30-7
18. Workman P, Walton MI, Lee FY. Benznidazole: nitroreduction and inhibition of cytochrome P-450 in chemosensitization of tumour response to cytotoxic drugs. Biochem Pharmacol 1986; 35 (1): 117-9
19. Lee FY, Workman P, Cheeseman KH. Misonidazole and benznidazole inhibit hydroxylation of CCNU by mouse liver microsomal cytochrome P-450 in vitro. Biochem Pharmacol 1987; 36 (8): 1349-55
20. Walton MI, Workman P. Nitroimidazole bioreductive metabolism: quantitation and characterisation of mouse tissue benznidazole nitroreductases in vivo and in vitro. Biochem Pharmacol 1987; 36 (6): 887-96
21. Gonzalez-Martin G, Thambo S, Paulos C, et al. The pharmacokinetics of nifurtimox in chronic renal failure. Eur J Clin Pharmacol 1992; 42 (6): 671-3
22. Paulos C, Paredes J, Vasquez I, et al. Pharmacokinetics of a nitrofuran compound, nifurtimox, in healthy volunteers. Int J Clin Pharmacol Ther Toxicol 1989; 27 (9): 454-7
23. Medenwald H, Brandau K, Schlossmann K. Quantitative determination of nifurtimox in body fluids of rat, dog and man. Arzneimittelforschung 1972; 22 (9): 1613-7
24. Duhm B, Maul W, Medenwald H, et al. Investigations on the pharmacokinetics of nifurtimox- 35 S in the rat and dog. Arzneimittelforschung 1972; 22 (9): 1617-24
25. Masana M, de Toranzo EG, Castro JA. Studies on nifurtimox nitroreductase activity in liver and other rat tissues. Arch Int Pharmacodyn Ther 1984; 270 (1): 4-10
26. de Andrade AL, Zicker F, de Oliveira RM, et al. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 1996; 348 (9039): 1407-13
27. Sosa ES, Segura EL. Treatment of Trypanosoma cruzi infection in the indeterminate phase: experience and current guidelines in Argentina [in Spanish]. Medization. cina (B Aires) 1999; 59 Suppl. 2: 166-70
28. Altcheh J, Biancardi M, Lapena A, et al. Congenital Chagas disease: experience in the Hospital de Ninos, Ricardo Gutierrez, Buenos Aires, Argentina [in Spanish]. Rev Soc Bras Med Trop 2005; 38 Suppl. 2: 41-5
29. Sosa ES, Segura EL, Ruiz AM, et al. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. Am J Trop Med Hyg 1998; 59 (4): 526-9
30. Moya PR, Paolasso RD, Blanco S, et al. Treatment of Chagas' disease with nifurtimox during the first months of life [in Spanish]. Medicina (B Aires) 1985; 45 (5): 553-8
31. Russomando G, Figueredo A, Almiron M, et al. Polymerase chain reaction-based detection of Trypanosoma cruzi DNA in serum. J Clin Microbiol 1992; 30 (11): 2864-8
32. Streiger ML, del Barco ML, Fabbro DL, et al. Longitudinal study and specific chemotherapy in children with chronic Chagas' disease, residing in a low endemicity area of Argentina [in Portugese]. Rev Soc Bras Med Trop 2004; 37 (5): 365-75
33. Streiger M, Fabbro D, del Barco M, et al. Congenital Chagas disease in the city of Santa Fe. Diagnosis and treatment [in Spanish]. Medicina (B Aires) 1995; 55 (2): 125-32
34. Altcheh J, Corral R, Biancardi MA, et al. Anti-F2/3 antibodies as cure marker in children with congenital Trypanosoma cruzi infection [in Spanish]. Medicina (B Aires) 2003; 63 (1): 37-40
35. Sosa-Estani S, Segura EL. Etiological treatment in patients infected by Trypanosoma cruzi: experiences in Argentina. Curr Opin Infect Dis 2006; 19 (6): 583-7
36. Sosa ES, Segura EL. Treatment of Trypanosoma cruzi infection in the undetermined phase: experience and current guidelines of treatment in Argentina. Mem Inst Oswaldo Cruz 1999; 94 Suppl. 1: 363-5
37. Schijman AG, Altcheh J, Burgos JM, et al. Aetiological treatment of congenital Chagas' disease diagnosed and monitored by the polymerase chain reaction. J Antimicrob Chemother 2003; 52 (3): 441-9
38. Viotti R, Vigliano C, Armenti H, et al. Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up. Am. Heart J 1994; 127 (1): 151-62
39. Fabbro DL, Streiger ML, Arias ED, et al. Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe city (Argentina), over a mean follow-up of 21 years: parasitological, serological and clinical evolution. Rev Soc Bras Med Trop 2007; 40 (1): 1-10
40. Fabbro DS, Arias E, Streiger M, et al. Evolutive behavior towards cardiomyopathy of treated (nifurtimox or benznidazole) and untreated chronic chagasic patients. Rev Inst Med Trop Sao Paulo 2000; 42 (2): 99-109
41. Viotti R, Vigliano C, Lococo B, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a non-randomized trial. Ann Intern Med 2006; 144 (10): 724-34
42. Marin-Neto JA, Rassi Jr A, Morillo CA, et al. Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). Am Heart J 2008; 156 (1): 37-43
43. Wilson JT. An update on the therapeutic orphan. Pediatrics 1999; 104 (3 Pt 2): 585-90
44. Nahata MC. Lack of pediatric drug formulations. Pediatrics 1999; 104 (3 Pt 2): 607-9
45. The therapeutic orphan: 30 years later. Proceedings of a joint conference of the Pediatric Pharmacology Research Unit Network, the European Society of Developmental Pharmacology, and the National Institute of Child Health and Human Development. Washington DC, USA, May 2, 1997. Pediatrics 1999; 104 (3 Pt 2): 581-645
46. Faria CR, Souza SEM, Rassi A. Polineuropatia periférica induzida por benzonidazol no tratamento da doença de Chagas. 129 [letter]. Arq Neuropsiq 1986; 44 (2): 125
47. Flores-Vieira CL, Barreira AA. Experimental benznidazole encephalopathy: I. Clinical-neurological alterations. J Neurol Sci 1997; 150 (1): 3-11
48. Flores-Vieira CL, Chimelli L, Franca Fernandes RM, et al. Experimental benznidazole encephalopathy: II. Electroencephalographic and morphological alterations. J Neurol Sci 1997; 150 (1): 13-25
49. WHO Expert Committee on the Control of Chagas Disease, World Health Organization. Report of the WHO Expert Committee on the Control of Chagas Disease, 2005. 905ed. Geneva: World Health Organization, 2005 [online]. Available from URL: http://www.who.int/tdr/publications/publications/pdf/ swg_chagas.pdf [Accessed 2008 Aug 28]
50. Sheiner LB, Rosenberg B, Marathe VV. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Bioto, pharm 1977; 5 (5): 445-79
51. Sheiner LB, Benet LZ, Pagliaro LA. A standard approach to compiling clinical pharmacokinetic data. J Pharmacokinet Biopharm 1981; 9 (1): 59-127
52. Sheiner LB. The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods. Drug Metab Rev 1984; 15 (1-2): 153-71
53. Sheiner LB, Ludden TM. Population pharmacokinetics/dynamics. Annu Rev Pharmacol Toxicol 1992; 32: 185-209
54. Duffull S, Waterhouse T, Eccleston J. Some considerations on the design of population pharmacokinetic studies. J Pharmacokinet Pharmacodyn 2005; 32 (3-4): 441-57
55. Duffull SB. Design of clinical pharmacology trials. Clin Exp Pharmacol Physiol 2001; 28 (11): 905-12
56. Meibohm B, Laer S, Panetta JC, et al. Population pharmacokinetic studies in pediatrics: issues in design and analysis. AAPS J 2005; 7 (2): E475-87
57. Roy A, Ette EI. A pragmatic approach to the design of population pharmacokinetic studies. AAPS J 2005; 7 (2): E408-20
58. Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetics parameters: I. Michaelis-Menten model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm 1980; 8 (6): 553-71
59. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for industry: population pharmacokinetics. 1999 [online]. Available from URL: http://www.fda.gov/CDER/guidance/1852fnl.pdf. [Accessed 2008 Aug 28]
60. Clinicaltrials.gov registry number NCT00699387 [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2008 Nov 18]